12 Best Medical Stocks To Buy Under $20

Page 11 of 11

1. Viatris Inc. (NASDAQ:VTRS)

Share Price as of January 8: $11.96

Number of Hedge Fund Holders: 57

Viatris Inc. (NASDAQ:VTRS) is a global pharmaceutical and healthcare company. With a goal to improve access to quality medicines, it serves more than 165 markets and territories around the globe. The company offers a variety of medicines, including branded prescription drugs, generics, vaccines, and medical devices. Viatris Inc. (NASDAQ:VTRS) ranks among the best medical stocks to invest in.

Viatris Inc. (NASDAQ:VTRS) continues to expand its product offerings through strategic partnerships. In October 2024, it entered an exclusive licensing agreement with Lexicon Pharmaceuticals for sotagliflozin outside the US and Europe. This agreement enhances the company’s cardiovascular portfolio.

The company is strategically focused on launching new products to grow its business. In the third quarter of 2024, Viatris Inc. (NASDAQ:VTRS) reported total revenues of $3.8 billion, with new product revenues accounting for $133 million. The company expects to generate between $500 million and $600 million from new products in 2024. This growth will be supported by the successful launch of innovative treatments like Breyna and lisdexamfetamine.

Overall, VTRS ranks first among the 12 best medical stocks to buy under $20. While we acknowledge the potential of medical companies, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VTRS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 11 of 11